12,937 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Acquired by Creative Planning

Creative Planning acquired a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 12,937 shares of the company’s stock, valued at approximately $371,000.

Other hedge funds have also recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its position in shares of Akero Therapeutics by 2,366.0% during the 1st quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after purchasing an additional 1,183 shares during the period. Headlands Technologies LLC boosted its position in Akero Therapeutics by 253.5% in the 1st quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock valued at $107,000 after buying an additional 3,024 shares during the period. Ameritas Investment Partners Inc. boosted its position in Akero Therapeutics by 20.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock valued at $156,000 after buying an additional 1,030 shares during the period. Virtu Financial LLC purchased a new position in Akero Therapeutics in the 1st quarter valued at approximately $270,000. Finally, Quest Partners LLC boosted its position in Akero Therapeutics by 22,021.1% in the 2nd quarter. Quest Partners LLC now owns 12,609 shares of the company’s stock valued at $296,000 after buying an additional 12,552 shares during the period.

Insider Activity

In other news, CEO Andrew Cheng sold 1,738 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $26.18, for a total value of $45,500.84. Following the sale, the chief executive officer now directly owns 605,417 shares in the company, valued at approximately $15,849,817.06. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO William Richard White sold 75,159 shares of Akero Therapeutics stock in a transaction on Monday, August 26th. The shares were sold at an average price of $27.21, for a total transaction of $2,045,076.39. Following the sale, the chief financial officer now directly owns 41,791 shares in the company, valued at $1,137,133.11. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Andrew Cheng sold 1,738 shares of Akero Therapeutics stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $26.18, for a total transaction of $45,500.84. Following the sale, the chief executive officer now owns 605,417 shares in the company, valued at $15,849,817.06. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 428,397 shares of company stock worth $12,997,971. 7.94% of the stock is currently owned by corporate insiders.

Akero Therapeutics Price Performance

Shares of AKRO opened at $34.87 on Friday. Akero Therapeutics, Inc. has a twelve month low of $13.39 and a twelve month high of $37.00. The firm’s fifty day simple moving average is $28.72 and its 200-day simple moving average is $25.04. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, August 9th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. As a group, equities research analysts expect that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a research report on Tuesday, September 17th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.20.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.